Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Nydrazid
Synonyms :
Isoniazid
Class :
Hydrazide derivatives
Brand Name :
Nydrazid
Synonyms :
Isoniazid
Class :
Hydrazide derivatives
Dosage Forms & StrengthsÂ
TabletsÂ
50mgÂ
100mgÂ
300mgÂ
Latent tuberculosis infection
:
>30kg:300mg orally every day for nine months
3-month regimen
900mg orally weekly once for three months
Active tuberculosis disease
5mg/kg orally/intramuscularly every day.Do not exceed 300mg every day
Dosage Forms & StrengthsÂ
TabletsÂ
50mgÂ
100mgÂ
300mgÂ
Latent tuberculosis infection
:
10-15mg/kg orally every day
3-month regimen
<2 years: Not recommended
>12 years: 900mg orally weekly once for three months
Active tuberculosis disease
10-15mg/kg orally every day. Do not exceed 300mg every day
Refer adult dosingÂ
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the levels of serum concentration of hormonal contraceptives
may decrease the therapeutic effect
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
may increase the serum concentration of CYP3A4 substrates
may enhance the serum concentrations of active metabolites
may diminish the serum concentration
may diminish the serum concentration
budesonide and formoterol (inhalation)Â
may enhance the serum concentration of CYP3A4 inhibitor
may diminish the serum concentration of CYP3A4 inducers
may enhance serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the serum concentration when combined with CYP3A4 Inducers (Strong)
may increase the serum concentration of abemaciclib
may increase the level of serum concentration of adagrasib
may increase or decrease the activity of this enzyme when combined with sparsentan
may diminish the serum concentration when combined with alfentanil
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with aripiprazole
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish the serum concentration when combined with atogepant
may diminish the serum concentration when combined with belumosudil
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with fenfluramine
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel: they may enhance serum concentrations of CYP2C19 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
diltiazem: they may diminish the serum concentration of CYP3A4 Inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
CYP3A4 inducers: they may diminish the serum concentration of eravacycline
erlotinib: they may diminish the serum concentration of CYP3A4 inducers
etoposide: they may diminish the serum concentration of CYP3A4 inducers
exemestane: they may diminish the serum concentration of CYP3A4 Inducers
felodipine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 inducers: they may diminish the serum concentration of ganaxolone
may diminish the serum concentration of zanubrutnib
drospirenone/ethinyl estradiol/levomefolateÂ
may diminish the serum concentration of Hormonal Contraceptives
may diminish the serum concentration of Voxelotor
brigatinib: they may diminish the serum concentration of CYP3A4 Inducers
daclatasvir: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of larotrectinib
lefamulin: they may diminish the serum concentration of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
maraviroc: they may diminish the serum concentration of CYP3A4 Inducers
mitapivat: they may diminish the serum concentration of CYP3A4 Inducers
perampanel: they may diminish the serum concentration of CYP3A4 Inducers
pirtobrutinib: they may diminish the serum concentration of CYP3A4 Inducers
praziquantel: they may diminish the serum concentration of CYP3A4 Inducers
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with methylprednisolone
may diminish the serum concentration of Hormonal Contraceptives
etonogestrel/ethinyl estradiolÂ
may diminish the serum concentration of Hormonal Contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with indinavir
avanafil: they may enhance the serum concentration of CYP3A Inhibitors
daridorexant: they may enhance the serum concentration of CYP3A Inhibitors
encorafenib: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
fexinidazole: they may diminish serum concentrations of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
midazolam: they may enhance the serum concentration of CYP3A Inhibitors
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
sirolimus: they may enhance the serum concentration of CYP3A4 Inducers
triazolam: they may enhance the serum concentration of CYP3A4 Inducers
ubrogepant: they may enhance the serum concentration of CYP3A Inhibitors
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
simvastatin: it may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with antihepaciviral products
the effect of isoniazid is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
they decrease the concentration of doravirine in the serum
may diminish the serum concentration
may diminish the serum concentration
they decrease the concentration of rilpivirine
may decrease the serum concentration of macimorelin
may enhance the serum concentration
may decrease the serum concentration of lenacapavir
they decrease the concentration of buprenorphine in the serum
may reduce the level of serum concentration of abemaciclib
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
they decrease the concentration of glasdegib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
may enhance the serum concentration of elbasvir/grazoprevir
it increases the concentration of CYP3A4 substrates in the serum
may enhance the serum concentration of tafamidis
may diminish the serum concentration when combined with tolvaptan
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of capmatinib
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
they decrease the concentration of lurbinectedin in the serum
may diminish the concentration of serum when combined with lemborexant
may enhance the concentration of serum when combined with CYP3A4 substrates
may enhance the concentration of serum when combined with CYP3A4 substrates
naxitinib: they may diminish the serum concentration of CYP3A4 Inducers
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cobimetinib: they may diminish the serum concentration of CYP3A4 Inducers
daridorexant: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of elacestrant
fedratinib: they may diminish the serum concentration of CYP3A4 Inducers
finerenone: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
ibrexafungerp: they may diminish the serum concentration of CYP3A4 Inducers
ivabradine: they may diminish the serum concentration of CYP3A4 Inducers
leniolisib: they may diminish the serum concentration of CYP3A4 Inducers
mavacamten: they may diminish the serum concentration of CYP3A4 Inducers
neratinib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olutasidenib: they may diminish the serum concentration of CYP3A4 Inducers
omaveloxolone: they may diminish the serum concentration of CYP3A4 Inducers
pemigatinib: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
selumetinib: they may diminish the serum concentration of CYP3A4 Inducers
sertraline: they may diminish the serum concentration of CYP3A4 Inducers
tazemetostat: they may diminish the serum concentration of CYP3A4 Inducers
ulipristal: they may diminish the serum concentration of CYP3A4 Inducers
venetoclax: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
vonoprazan fumarate: they may enhance the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with isavuconazonium sulfate
may diminish the serum concentration when combined
may diminish the concentration of serum when combined with antihepaciviral products
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with dasabuvir
may diminish the concentration of serum when combined with entrectinib
they decrease the concentration of active metabolites of tamoxifen in serum
aprepitant: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
ivabradine: they may enhance the serum concentration of CYP3A Inhibitors
lomitapide: they may enhance the serum concentration of CYP3A Inhibitors
pacritinib: they may enhance the serum concentration of CYP3A Inhibitors
sertindole: they may enhance the serum concentration of CYP3A Inhibitors
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
antacids reduce the systemic absorption of isoniazid
antacids reduce the systemic absorption of isoniazid
antacids reduce the systemic absorption of isoniazid
antacids reduce the systemic absorption of isoniazid
antacids reduce the systemic absorption of isoniazid
may reduce the level of serum concentration of estrogen drugs
bazedoxifene/conjugated estrogens
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may have an increased hepatotoxic effect when combined with acetaminophen
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
dihydroergotamine intranasal and isoniazid are both known to elevate serotonin levels
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
isoniazid: they may diminish the absorption of antacids
isoniazid: they may diminish the absorption of antacids
isoniazid: they may diminish the absorption of antacids
isoniazid: they may diminish the absorption of antacids
isoniazid: they may diminish the absorption of antacids
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
when bromazepam and isoniazid are used together, there is a potential reduction in the bromazepam's metabolism
When alprazolam and isoniazid is used together, this leads to reduction in the alprazolam’s metabolism
When dexrabeprazole and isoniazid is used together, this leads to reduction in the dexrabeprazole’s metabolism
It may enhance the risk of adverse effects when combined with Mycolic acid inhibitors
It may enhance the risk of adverse effects when combined with Mycolic acid inhibitors
isoniazid: they may diminish the absorption of antacids
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
when both drugs are combined, there may be a reduced metabolism of etoposide   
when both drugs are combined, there may be a decreased metabolism of vincristine  
has a synergistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
when both drugs are combined, there may be an increased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may decrease the levels of serum concentration of clozapine
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may diminish the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration of CYP3A4 substrates
may decrease the serum concentration of erdafitinib.
azelastine/fluticasone intranasalÂ
may enhance the serum concentration
may decrease the serum concentration of macitentan
may enhance the serum concentration of macitentan
may decrease the level of serum concentration of pretomanid
CYP3A4 Inducers may decrease the serum concentration of eliglustat
may decrease the serum concentration of encorafenib
may decrease the serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may diminish the serum concentration of corticosteroids
may increase the hepatotoxic effect of acetaminophen
may increase the serum concentration
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may enhance serum concentrations when combined with doxercalciferol
may increase the level of serum concentration of itraconazole
may decrease the level of serum concentrations of itraconazole
may diminish the serum concentration when combined with selpercatinib
may diminish the serum concentration when combined with nimodipine
may diminish the serum concentration when combined with upadacitinib
may reduce the levels of serum concentration of tivozanib
may diminish the serum concentration of lidocaine
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined
eszopiclone: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
hydrocodone: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
meperidine: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may enhance the serum concentration of Buprenorphine
estrogens esterified/methyltestosterone            Â
may diminish the serum concentration when combined
may increase the hepatotoxic effect when combined
may enhance the concentration of serum when combined with fluticasone
aprepitant: they may diminish the serum concentration of CYP3A4 Inducers
codeine: they may diminish serum concentrations of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
diazepam: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
fentanyl: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
idelalisib: they may diminish the serum concentration of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
imatinib: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
istradefylline: they may diminish the serum concentration of CYP3A4 inducers
lapatinib: they may diminish the serum concentration of CYP3A4 Inducers
lercanidipine: they may diminish the serum concentration of CYP3A4 Inducers
levamlodipine: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
midazolam: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with taurursodiol
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naloxegol: they may diminish the serum concentration of CYP3A4 Inducers
nilvadipine: they may diminish the serum concentration of CYP3A4 Inducers
osimertinib: they may diminish the serum concentration of CYP3A4 Inducers
oxycodone: they may diminish the serum concentration of CYP3A4 Inducers
prednisone: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quinidine: they may diminish the serum concentration of CYP3A4 Inducers
quinine: they may diminish the serum concentration of CYP3A4 Inducers
regorafenib: they may diminish the serum concentration of CYP3A4 Inducers
repaglinide: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
samidorphan: they may diminish the serum concentration of CYP3A4 Inducers
sildenafil: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
ticagrelor: they may diminish serum concentrations of CYP3A4 Inducers
tofacitinib: they may diminish the serum concentration of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
trabectedin: they may diminish the serum concentration of CYP3A4 Inducers
tramadol: they may diminish the serum concentration of CYP3A4 Inducers
trazodone: they may diminish the serum concentration of CYP3A4 Inducers
tucatinib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
verapamil: they may diminish the serum concentration of CYP3A4 Inducers
vilazodone: they may diminish the serum concentration of CYP3A4 Inducers
zolpidem: they may diminish the serum concentration of CYP3A4 Inducers
zopiclone: they may diminish the serum concentration of CYP3A4 Inducers
may decrease the concentration of serum when combined with methylergometrine
cyclosporine: they may enhance the serum concentration of CYP3A4 Inhibitors
ixabepilone: they may enhance the serum concentration of CYP3A Inhibitors
nimodipine: they may enhance the serum concentration of CYP3A Inhibitors
tacrolimus: they may enhance the serum concentration of CYP3A Inhibitors
may diminish the serum concentration of each other when combined
may diminish the concentration of serum when combined with artemether and lumefantrine
may diminish the concentration of serum when combined with atazanavir
benzhydrocodone/acetaminophenÂ
may diminish the concentration of serum when combined with benzhydrocodone
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
it decreases the concentration of CYP3A4 inducers in serum
mometasone (Nasal): they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
clozapine: they may enhance the serum concentration of CYP3A Inhibitors
darifenacin: they may enhance the serum concentration of CYP3A Inhibitors
eszopiclone: they may enhance the serum concentration of CYP3A inhibitors
fedratinib: they may enhance the serum concentration of CYP3A inhibitors
lapatinib: they may enhance the serum concentration of CYP3A inhibitors
It may enhance the risk of adverse effects when combined with CYP3A4 inducers
rolapitant: they may diminish the serum concentration of CYP3A4 Inducers
nicardipine: they may diminish the serum concentration of CYP3A4 Inducers
dapoxetine: they may diminish the serum concentration of CYP3A4 Inducers
brimonidine: they may diminish the serum concentration of CYP3A4 Inducers
cimetidine: they may diminish the serum concentration of CYP3A4 Inducers
diazoxide: they may diminish the serum concentration of CYP3A4 Inducers
flunarizine: they may diminish the serum concentration of CYP3A4 Inducers
melatonin: they may diminish the serum concentration of CYP3A4 Inducers
methylphenidate: they may diminish the serum concentration of CYP3A4 Inducers
molsidomine: they may diminish the serum concentration of CYP3A4 Inducers
atosiban: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
dimercaprol: they may diminish the serum concentration of CYP3A4 Inducers
cannabis: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
tacrolimus: they may enhance the serum concentration of CYP3A4 Substrates
warfarin: they may enhance the serum concentration of CYP3A4 inducers
tricyclic antidepressants: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
an increase in rate of metabolism may be seen
metronidazole/tetracycline/bismuth subsalicylateÂ
by altering CYP2E1 metabolism, the levels of isoniazid may be increased with metronidazole
When isoniazid is aided by hesperetin, it reduces hesperetin’s metabolism
tenofovir disoproxil fumarate or tenofovir DFÂ
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
it may reduce the therapeutic effect
isoniazid, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
Actions and spectrum:
It inactivates the growth of mycobacterium through mycolic acids production. Because of this action, INH has strong bactericidal properties and also works in concert with other species that KatG produces and other TB treatments.
Frequency defined:
>10%
Peripheral neuropathy
Nausea
Stomach pain
Loss of appetite
Vomiting
Weakness
1-10%
Dizziness
Hyperreflexia
<1%
Anemia
Thrombocytopenia
Agranulocytosis
Megaloblastic anemia
Systemic lupus erythematous
Black Box Warning:
Fatal hepatitis
Contraindication:
Hypersensitivity
Cautions:
Renal/Hepatic impairment
Pregnancy consideration: CÂ
Lactation: The drug is excreted in the human breast milk and is safe for nursing women Â
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
<b>Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacodynamics:
It is effective against mycobacterium species.
It is a highly specialized agent that does not work against other microbes.
When mycobacteria grow quickly, isoniazid is bactericidal; when they grow slowly, it is bacteriostatic.
Pharmacokinetics:
Absorption
Rapid absorption
Peak plasma time is achieved in 1 to2 hours
Distribution
It is distributed widely throughout CSF’s tissues and fluids.
It is also known to cross the placenta and be excreted in breast milk.
10 to 15% of the drug is bound to plasma proteins.
Metabolism
Isoniazid undergoes hepatic metabolism.
Elimination and excretion
50 to 70% of the drug is eliminated through urine.
Half-life
Slow acetylators- 2 hours to 5 hours
Fast acetylators- 0.5 hours to 1.6 hours
Administration:
Isoniazid can be administered orally/IV as advised by the physician.
Patient information leaflet
Generic Name: isoniazid
Pronounced: [eye-so-NYE-a-zid]
Why do we use isoniazid?
Isoniazid is an antibiotic used to treat and prevent tuberculosis (TB).
It belongs to a class of antibiotics called antituberculosis agents.
Isoniazid is used to treat TB infections in the lungs and other parts of the body.
It is typically used in combination with other TB medications to ensure that the infection is fully treated and to prevent the development of drug-resistant TB
Isoniazid is an antibiotic used to treat and prevent tuberculosis (TB).
It belongs to a class of antibiotics called antituberculosis agents.
Isoniazid is used to treat TB infections in the lungs and other parts of the body.
It is typically used in combination with other TB medications to ensure that the infection is fully treated and to prevent the development of drug-resistant TB
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
